Siemens expands Gamma agreement:
This article was originally published in Clinica
Executive Summary
Malvern, Pennsylvania-based subsidiary of Siemens Medical Solutions has gained exclusive worldwide marketing rights to Gamma Medica's molecular imaging product, X-Spect, following an extension of the original agreement in July which had restricted Siemens' rights to the US. X-Spect is a dual modality system for pre-clinical imaging, combining functional nuclear imaging technique with anatomical imaging provided by computed tomography. Since the two companies signed the deal, rocketing sales of X-Spect have led Gamma Medica, of Northridge, California, to record a 400% increase in revenues during its fiscal 2004.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.